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Abstract  
Objective 
Intravenous thrombolysis and endovascular therapy (IVT/EVT) are evidence-based 
treatments for adults with arterial ischemic stroke (AIS). However, randomized controlled 
trials in pediatric patients are lacking. This study aimed to describe feasibility, safety, and 
outcome of IVT/EVT in children with AIS. 
Methods  
Retrospective study (01/2000–12/2015) of a multicenter, population-based consecutive 
cohort of patients aged 1 month – 16 years diagnosed with AIS presenting with a pedNIHSS 
≥4. Clinical and radiological data of patients receiving IVT/EVT were compared to those 
receiving standard care (SC) using linear regression to adjust for potential confounders. EVT 
included intraarterial thrombolysis and/or mechanical thrombectomy. Outcome was assessed 
6 months after stroke using the pediatric stroke outcome measure (PSOM). 
Results 
Overall, 150 patients (age 7.1+/-4.9 years, 55 [37%] females) presented with a pedNIHSS of 
>4. Recanalization treatment was performed in 16 [11%], of whom 5 [3%] were treated with 
IVT and 11 [7%] with EVT. Patients receiving recanalization treatment were older (mean age 
11.0 versus 6.9 years, p=0.01) and more severely affected (median pedNIHSS 13.5 versus 
8.0, p<0.001). Death and bleeding complications did not differ between the two groups. 
Median (IQR) PSOM 6 months after AIS was 2.5 (1–4.3) and 1(0–2) in the IVT/EVT and SC 
groups, respectively (p=0.014). However, after multiple linear regression analysis, only 
higher baseline pedNIHSS remained associated with an unfavorable outcome (p<0.001). 
Interpretation 
Recanalization treatment is feasible and seems to be safe in severely affected pediatric AIS 
patients. The assessment of efficacy of IVT/EVT in pediatric stroke patients requires larger 
studies. 
Introduction  
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Childhood arterial ischemic stroke (AIS) is a devastating disease affecting approximately 2–
5:100,000 children per year. It is associated with significant morbidity and mortality and 
carries a high socioeconomic burden.1-3 For adults, there are now highly effective treatment 
options for acute AIS consisting of intravenous thrombolysis or endovascular therapy (EVT), 
i.e. endovascular thrombolysis or mechanical thrombectomy. In particular, intravenous 
thrombolysis (IVT) with alteplase has been shown to significantly reduce disability in stroke 
patients without increasing mortality if given up to 4.5 hours after symptom onset.4 Recently, 
endovascular thrombectomy in combination with best medical therapy has been shown to be 
highly effective in AIS patients with a large vessel occlusion in the anterior circulation, with a 
number needed to treat of 2.6.5 
 
In contrast to the adult population, evidence from randomized studies of recanalization 
treatments in children is lacking. The prospective randomized controlled trial TIPS 
(thrombolysis in pediatric stroke) failed to recruit patients due to late arrival at hospital, 
diagnostic delay and the lack of established acute stroke programs.6, 7 Further trials 
assessing recanalization treatment in pediatric stroke patients are unlikely considering the 
clinical and ethical difficulties in randomizing pediatric stroke patients who are candidates for 
the treatment and also with regard to the overwhelming efficacy of these therapies in adults.8 
 
Stroke etiologies in children differ from those in adults and therefore, results cannot simply 
be extrapolated to pediatric stroke patients. Most centers agree on the use of aspirin or 
heparin for the treatment of acute stroke in children with AIS. The use of recanalization 
treatment, i.e. IVT or EVT in pediatric AIS has been reported.9-15 However, population-based 
data on recanalization treatments in pediatric stoke patients are lacking. Therefore, we aimed 
to assess feasibility, safety and outcome of AIS patients treated with IVT/EVT in the 
population-based Swiss NeuroPediatric Stroke Registry (SNPSR). 
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Methods 
Study Design and Study Population 
This is a cohort study of consecutive pediatric AIS patients included in the SNPSR. The 
SNPSR is a nationwide prospective registry that includes all pediatric AIS patients living in 
Switzerland.1, 3 All children aged 1 month to 16 years diagnosed with AIS between 2000 and 
2015 who had a pediatric National Institutes of Health Stroke Scale (pedNIHSS) score >4 at 
presentation were included. Patients with neonatal stroke or cerebral venous thrombosis 
were excluded. AIS was defined as a new focal neurological deficit with ischemic lesion 
visible on magnetic resonance imaging (MRI) in the corresponding vascular territory. Patients 
who received recanalization treatment, i.e. IVT, endovascular pharmacological and/or 
mechanical treatment or a combination of both – later called the recanalization group – were 
compared to those receiving standard care (SC). 
 
Variables at Stroke Onset 
Baseline characteristics (i.e. demographic data, vascular risk factors, laboratory findings), 
treatment modalities, and time from symptom onset to diagnosis and treatment were 
recorded. Stroke severity was assessed using the pedNIHSS. Patients diagnosed before 
2011 were scored for pedNIHSS retrospectively.16, 17 All patients underwent MRI or computed 
tomography imaging to rule out intracranial hemorrhage, and MR angiography to assess the 
site of vessel occlusion. 
Intravenous and endovascular therapies for children were adapted based on international 
and institutional guidelines for adult stroke patients. In general, IVT was performed with 
either full-dose (0.9 ml/kg body weight) or 2-thirds-dose (0.6 ml/kg body weight) of 
intravenous tissue plasminogen activator (tPA) within 4.5 hours after symptom onset. In 
patients with basilar artery occlusions, or in selected cases, extended time windows were 
applied based on imaging. EVT was performed if: 1) diagnosis of ischemic stroke was 
established; 2) baseline pedNIHSS score was ≥ 4 points; 3) hemorrhage on cranial CT or 
MRI was excluded; 4) vessel occlusion correlated with the neurological deficit; and 6) no 
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individual clinical or premorbid conditions or laboratory findings contraindicated 
thrombolysis.18, 19 However, the final decision on treatment was at the discretion of the 
neuropediatricians, neurologists and interventional neuroradiologists on call.  
Digital subtraction angiography was performed via the transfemoral approach. 
Endovascular recanalization procedures consisted of a combination of techniques such as 
intraarterial pharmacological treatment (urokinase, n = 2; iv tPA, n = 12; eptifibatide, n = 1) or 
mechanical thrombectomy. Device selection depended on occlusion pattern and operator 
preference: mechanical recanalization was performed using thromboaspiration and stent 
retrievers. Immediately after IVT and/or EVT all patients were transferred to the pediatric 
intensive care unit. Twenty-four hours after treatment, or earlier in the case of clinical 
deterioration, a CT or MRI scan was performed. Recanalization rates were classified as 
complete, partial, or no recanalization by the responsible neuroradiologists. Symptomatic 
intracerebral hemorrhage (sICH) and asymptomatic intracerebral hemorrhage (aICH) were 
classified according to the European Cooperative Acute Stroke Study (ECASS) III study 
protocol.20, 21 Non-thrombolysed patients were transferred either to the pediatric intensive 
care unit or to the pediatric ward. They were treated, according to the discretion of the 
responsible neuropediatrician, mainly with aspirin and/or heparin. 
Etiology of stroke was assessed using the Cascade classification.22 Complete stroke 
workup was defined according to the recommendations in the SNPSR and included 
echocardiography, MRI and vessel imaging of head and neck as well as screening for 
infection, metabolic disease, coagulation pathology and vasculitis. Complications assessed 
were as follows: malignant middle cerebral artery infarct (MMCAI), sICH, aICH, any bleeding, 
or stroke-related mortality.19 Neuropediatricians examined all patients 6 months after stroke 
onset. Disability was scored using the pediatric stroke outcome measure (PSOM), in some 
cases retrospectively.23-25 
 
Statistical analysis 
We primarily assessed feasibility, safety and outcome of recanalization treatment in pediatric 
AIS patients 6 months after AIS treatment. Secondary outcomes included the PSOM at 
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discharge and 2 years after AIS, treatment-related complications, and stroke-related 
mortality. Variables were summarized descriptively by treatment type for all the patients 
included and no imputation of missing variables was performed. Between-group comparisons 
for categorical variables were made using the Chi-Square or Fisher’s exact test, as 
appropriate, and for continuous variables using the Wilcoxon rank sum test. Adjustment for 
potential confounders was performed using a multiple linear regression model. Besides 
modality of treatment (recanalization treatment versus SC), variables included in the linear 
regression model were chosen according to the results from univariate analysis (p<0.2). We 
performed two subgroup analyses: the first controlled for initial pedNIHSS; i.e. eliminated 
patients in the SC group with a pedNIHSS below 10. The second compared patients treated 
with thrombolysis (IVT and IAT) to endovascular thrombectomy (use of MT). A 2-sided p-
value of <0.05 was considered statistically significant. Analysis was performed using R 
(version 3.1.2 – R Core Team (2014)). The SNPSR was approved by the cantonal ethics 
boards and by the Swiss Ministry of Health. All patients and/or their legal guardians 
participating in the SNPSR provided written informed consent. In addition, the approval of the 
Swiss Ministry of Health allows for the collection of basic information on all Swiss pediatric 
stroke patients.  
 
Results 
Description of the Cohort 
A total of 216 children were diagnosed with an AIS during the study period and 150 patients 
(mean [SD] age 7.1 [4.9]  years, 55 [37%]  females) with a pedNIHSS of >4 were included in 
this analysis. Sixteen of the 150 patients (11%) received IVT or EVT. Recanalization 
treatment was not used in any patient with a pedNIHSS <4. Baseline characteristics of the 
cohort are presented in Table 1. Stroke etiology remained undetermined in 64 (42.7%) 
patients; 18% had a stroke with a cardioembolic origin and 17.3% had a focal cerebral 
arteriopathy. One hundred and twenty patients (80%) had an anterior circulation stroke, of 
whom 17 (11.3%) developed a MMCAI. Overall, four patients (2.7%) died because of the 
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stroke. Median PSOM during follow-up was 1.0 (interquartile range [IQR] 0.5–2.5) at all time 
points of assessment, i.e. at discharge, 6 and 24 months after AIS. 
 
Description of Patients in the Recanalization Group 
Detailed information on the 16 patients (mean [SD] age 11.0 [4.3] years, 31.2% female, 
median [IQR] pedNIHSS 13.5 [11.5–21.3]) who received recanalization treatment is given in 
Table 2. All but one patient (patient 5) were diagnosed within 12 hours after symptom onset; 
however 4 patients were treated more than 6 hours after symptom onset. All these patients 
had an occlusion of the basilar artery. Three patients had a stroke due to unilateral focal 
cerebral arteriopathy and 4 patients due to cardioembolism. Stroke etiology remained 
undetermined in the remaining nine patients. Of the latter, 3 had risk factors associated with 
childhood stroke (Evans syndrome with hemolysis and homozygous MTHFR mutation in 
patient 6, decreased protein S in patient 8, and elevated lipoprotein a in patient 15). Five 
patients (31.2%) had a basilar artery occlusion, 7 (43.8%) an MCA and 4 (25%) an ICA 
occlusion. Five patients (31.2%) were treated with IVT only and five patients received 
intraarterial pharmacological treatment either with tPA or urokinase. The remaining 6 patients 
were treated with mechanical thrombectomy; one of these patients received pretreatment 
with IVT and 4 patients received additional intraarterial pharmacological treatment. Only one 
patient was treated with mechanical thrombectomy alone. 
Complications of recanalization therapy occurred in two patients (12.5%): one patient 
experienced an asymptomatic ICH and one mucosal bleeding. Furthermore, 5 patients 
developed an MMCAI requiring hemicraniectomy and one of these patients died due to 
massive herniation. The indication for hemicraniectomy was based on evolving mass effect 
due to infarct growth and malignant edema over 24-48 hours post stroke. There was neither 
any evidence of hemorrhages nor reinfarctions in these patients. The pedNIHSS of patients 
with MMCAI ranged between 14–21. Recanalization was assessed immediately after the 
intervention in those patients receiving endovascular treatment and within the first 24 hours 
in those receiving IVT.  Complete recanalization at follow-up was seen in 4 (25%), partial in 6 
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(38%) and no recanalization in 4 (25%) patients. Information on recanalization rates was 
lacking for 2 (12%) patients. None of the patients developed a new thrombus. All patients 
who showed no recanalization at follow-up had been treated with IVT more than 6 hours after 
symptom onset. Median (IQR) PSOM 6 months after stroke was 2.5 (1.0–4.3). Overall, the 
use of recanalization treatment increased over the years of the study (Figure 1). The 
comparison of patients treated with thrombolysis, i.e. IVT and IAT, and endovascular 
thrombectomy, i.e. use of MT, did not reveal any statistically different results (table 3).   
 
Comparison of Recanalization Treatment with Standard Care 
Significant differences were noted between patients who received recanalization treatment 
and those who did not: in univariate analysis patients who had recanalization treatment were 
older (p = 0.001), had a higher baseline pedNIHSS (p<0.001), and a shorter time interval 
from symptom onset to diagnosis (p<0.001). However, stroke etiology and the site of vessel 
occlusion did not differ between the 2 groups (Table 1). Overall, in univariate analyses 
bleeding complications did not occur significantly more frequently in patients who had 
recanalization treatment than in patients receiving SC, whereas MMCAI was diagnosed in 5 
patients (31.2%) in the recanalization group compared to 12 (9%) in the SC group (p = 
0.012). Median (IQR) PSOM at 6 months was 2.5 (1.0–4.3) in the recanalization and 1.0 (0–
2.0) in the SC group (p = 0.014; Table 1). However, in a multiple regression analysis after 
adjusting for age, baseline pedNIHSS, diagnostic delay and modality of treatment, only 
higher baseline pedNIHSS was associated with a higher PSOM 6 months after stroke, but 
not recanalization treatment (Supplementary table 1). Eliminating the impact of initial 
pedNIHSS by excluding patients with an initial pedNIHSS of <10 in the SC group, the PSOM 
6 months after stroke did not differ anymore between groups (table 4 and supplementary 
table 2).  
 
Discussion 
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Whether IVT and endovascular treatment approaches are feasible, safe and effective in 
children who have had an acute ischemic stroke is currently one of the most pressing 
questions in pediatric stroke research. The main findings of our population-based series of 
consecutive pediatric AIS patients treated with various recanalization approaches were: 1) 
recanalization treatment is feasible, and 16 out of 150 acute stroke patients with a pedNIHSS 
of ≥4 were treated with either IVT or EVT; 2) complications did not occur more frequently in 
patients who received recanalization treatment; 3) patients who received IVT and EVT had 
suffered a more severe stroke were more severely affected; 4) mortality did not differ 
between the 2 treatment groups and, 5) in multivariate analysis, stroke severity, as evaluated 
by pedNIHSS, was the only significant predictor of unfavorable outcome according to PSOM. 
 
Rates of Revascularization Procedures 
This population-based cohort study supports the view that recanalization therapy in children 
is used rarely (~10%); however, an increase in its use over time was noted (Figure 1). The 
most likely reasons for the low usage are lack of evidence available from randomized 
controlled trials, late presentation, diagnostic delay and uncertainty regarding safety and 
clinical efficacy. In our cohort, one-third of patients were diagnosed more than 24 hours after 
symptom onset; thus, recanalization treatment was no longer possible. Even though we 
observed an increase in early presentation over time, resulting in a higher proportion of 
pediatric AIS patients being diagnosed and treated early, there is still an urgent need to 
increase awareness of stroke in the pediatric population to allow more pediatric AIS patients 
to be evaluated for recanalization treatment (Figure 2). 
 
Revascularization techniques 
The use of the different revascularization techniques was performed individually according to 
the discretion of the interdisciplinary team on call. Performing a subgroup analysis comparing 
the use of thrombolysis to endovascular thrombectomy we could not show any statistically 
significant difference regarding recanalisation rates and outcome. However, the potential 
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impact of the technique on outcome is important and requires further attention in future 
studies focusing on pediatric stroke treatments.  
 
Safety 
One of the major concerns of neuropediatricians about the use of acute recanalization 
techniques in children relates to their safety, e.g. the potential for disabling or even fatal 
bleeding complications. However, no severe or fatal treatment-related complications 
occurred in our study, which is in line with previous reports.9, 10, 12 Rates of hemorrhagic 
transformations and mortality did not differ between the 2 treatment groups. Furthermore, no 
complications occurred during endovascular procedures. This finding is in line with those of 
recent reviews reporting low complication rates in children who received endovascular 
treatment for AIS. This is important as stroke etiologies in children differ from adults and 
therefore the results of randomized controlled trials cannot simply be extrapolated to 
pediatric stroke patients.26 Children more often have strokes due to an underlying 
arteriopathy, especially of inflammatory origin, which might increase the risk of bleeding 
complications during endovascular procedures, due to vessel fragility. In our cohort we had 
only one patient with FCA who underwent endovascular treatment and, therefore, no  firm 
conclusions regarding its influence on outcome are possible. However, vascular fragility and 
risk of hemorrhage needs to be considered and weighted carefully against a potential benefit 
of a recanalisation treatment in this specific patient population. Future research should 
include consideration of stroke etiology when assessing recanalization techniques. 
 
Four patients received IVT more than 4.5 hours after symptom onset and none of these 
patients recanalized. No bleeding complications occurred in these patients, but they also 
showed no clear benefit from IVT. Therefore, in pediatric stroke patients, as in adults, the 
benefit  of IVT more than 4.5 hours after stroke is questionable. 
 
Severity of AIS 
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Patients receiving IVT and EVT were more severely affected than those receiving SC 
(pedNIHSS 13.5 versus 8.0; p<0.001). MMCAI is a serious concern in patients suffering from 
a large anterior circulation stroke. In our cohort, development of MMCAI occurred in 17 
patients (i.e. 17% of all MCA strokes) and was more frequent in patients receiving 
recanalization treatment than in the SC group. The frequency of MMCAI ranges between 
1.3–18% in pediatric AIS patients and is associated with higher baseline pedNIHSS as 
shown in our cohort.27-29 Therefore, the higher frequency of MMCAI in the recanalization 
group is likely to be an epiphenomenon of more severe infarcts, rather than a complication 
attributable to the treatment modality itself. 
 
Mortality 
Mortality in patients treated with recanalization techniques was not higher than in the SC 
group, despite a higher baseline pedNIHSS. Compared to the SOC group, patients receiving 
recanalization treatment had a worse neurological outcome at discharge and 6 months post-
stroke (Table 1). However, after adjusting for age, baseline pedNIHSS and diagnostic delay, 
treatment modality was not a predictor of unfavorable outcome. The initial severity of the 
stroke was the only relevant factor associated with unfavorable outcome. This finding was 
confirmed by a subgroup analysis controlling for initial pedNIHSS.  
 
Outlook  
Evidence from randomized trials as to whether recanalization techniques in pediatric patients 
are safe and clinically effective is needed. However, a previous prospective randomized 
controlled trial (TIPS) failed to recruit patients, and further trials assessing recanalization 
treatment in the pediatric stroke population are unlikely. This is because of the clinical and 
ethical difficulties in randomizing pediatric stroke patients against the background of 
overwhelming evidence for a very strong treatment effect in adults. Therefore, alternative 
approaches such as large international prospective treatment registries allowing for data 
pooling and matching are urgently needed to gain further insights into optimal treatment 
regimens for pediatric stroke patients. In the meantime, standardized treatment protocols and 
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recommendations should be developed and implemented to provide guidance for 
neuropediatricians treating pediatric stroke patients.7 
 
A major strength of our study is the population-based nature of the SNPSR and the relatively 
large sample size. One major limitation is the inhomogeneous cohort, with anterior and 
posterior circulation stroke patients treated with different treatment modalities. Another is the 
absence of standardized protocols in the different centers. Some patients with basilar artery 
occlusion were thrombolysed more than 6 hours after symptom onset, which is not evidence 
based in the adult population. The small sample size, especially in the interventional 
treatment group, clearly restricts the statistical power of comparisons and multiple 
regression. Therefore, non-significant findings have to be interpreted with caution. 
Furthermore, treatment approaches have dramatically changed during the past 10 years and, 
given the sample size, we were not able to restrict the analysis to the past 5 years. Finally, to 
assess efficacy of recanalization treatment, a more homogeneous cohort, standardized 
assessment of recanalization status and a matched analysis would have been valuable.  
 
Conclusions 
Recanalization treatment appears to be a feasible and safe treatment option for pediatric AIS 
patients. A large proportion of such patients are still diagnosed too late, missing the 
opportunity to be assessed for recanalization treatment options. Previous attempts have 
shown that a randomized controlled trial of acute stroke treatment in pediatric patients is not 
feasible. Therefore, larger prospective population-based registries are needed to allow for 
matching and data pooling to identify those patients most likely to benefit from recanalization 
treatment.   
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Legend of abbreviations: 
ACA: anterior cerebral artery 
BA: basilar artery 
CE: cardioembolic 
FCA: focal cerebral arteriopathy 
IAT: intrarterial thrombolysis 
ICA: Internal carotid artery 
ICH: intracerebral hemorrhage 
IVT: intravenous thrombolysis 
MCA M1: M1 segment of the middle cerebral 
artery 
MCA M2: M2 segment of the middle cerebral 
artery 
MMCAI: malignant middle cerebral artery 
infarction 
MT: mechanical thrombectomy 
NA: not available 
PCA: posterior cerebral artery 
PICA: posterior inferior cerebellar artery 
PSOM: pediatric stroke outcome measure 
SCA: superior cerebellar artery 
SVA: small vessel arteriopathy 
ttm: treatment 
UE: undetermined etiology 
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Figure legends 
Figure 1 shows the frequency of recanalization treatment per 2-year period during the study. 
Figure 2 shows the proportion of pediatric AIS patients diagnosed within 6 hours from 
symptom onset during the study period. 
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Table 1. Baseline characteristics of the cohort (pedNIHSS >4) 
 Whole cohort 
(150) 
Recanalization 
ttm (16) 
Standard ttm 
(134) 
p-value* 
Age (years), mean (SD) 7.1 (4.9) 11.0 (4.3) 6.7 (4.8) 0.001 
Sex, f (%) 55 (36.7) 5 (31.2) 50 (37.3) 0.786 
pedNIHSS, median (IQR) 8.0 (5.8-12-0) 13.5 (11.5-21.3) 8 (5-11) <0.001 
Fever, n (%) 11 (7.3) 0 (0) 11 (8.2) 1.0 
Seizure, n (%) 39 (26.0) 5 (31.2) 34 (25.4) 1.0 
Stroke classification, n (%) 
SVA 
FCA 
bilateral arteriopathy 
aortic/cervical 
arteriopathy  
cardioembolic 
undetermined 
multifactorial 
 
5 (3.3) 
26 (17.3) 
4 (2.7) 
17 (11.3) 
 
27 (18.0) 
64 (42.7) 
7 (4.7) 
 
0 
3 (18.8) 
0 
0 
 
4 (25.0) 
9 (56.2) 
0 
 
5 (3.7) 
23 (17.2) 
4 (3.0) 
17 (12.7) 
 
23 (17.2) 
55 (41.0) 
7 (5.2) 
0.685 
Site of stroke, n (%) 
Right 
Left 
Bilateral  
 
61 (40.7) 
68 (45.3) 
21 (14.0) 
 
6 (37.5) 
6 (37.5) 
4 (25.0) 
 
55 (41.0) 
62 (46.3) 
17 (12.7) 
0.415 
Site of proximal vessel 
occlusion  
ICA 
MCA 
ACA 
PCA 
BA 
SCA/PICA 
 
 
20 (13.3) 
100 (66.7) 
- 
10 (6.7) 
15 (10.0) 
5 (3.3) 
 
 
4 (25.0) 
7 (43.8) 
- 
- 
5 (31.2) 
- 
 
 
16 (11.9) 
93 (69.4) 
- 
10 (7.5) 
10 (7.5) 
5 (3.7) 
0.450 
Delay, n (%) 
<= 6h 
>6 - <=12h 
>12 - <=24h 
>24h 
 
47 (31.3) 
18 (12.0) 
29 (19.3) 
51 (34.0) 
 
12 (75.0) 
3 (18.8) 
0 (0) 
1 (6.2) 
 
35 (27.1) 
15 (11.6) 
29 (22.5) 
50 (38.8) 
<0.001 
Treatment, n (%) 
IVT 
IAT 
MT 
 
- 
- 
- 
 
5 (31.2) 
8 (50.0) 
3 (18.8) 
 
- 
NA 
Complications, n (%) 
symptomatic ICH 
asymptomatic ICH 
systemic bleeding 
any bleeding 
 
0 
3 (2.0) 
0 
2 (1.3) 
 
0 
1 (6.2) 
0 
1 (6.2) 
 
0 
2 (1.5) 
0 
1 (0.7) 
 
 
0.200 
 
0.070 
MMCAI, n (%) 17 (11.3) 5 (31.2) 12 (9.0) 0.012 
Stroke related mortality  4 (2.7) 1 (6.2) 3 (2.3) 0.377 
PSOM, median (IQR)** 
Discharge, n=142 
6 months, n=117 
24 months, n=86 
 
1.0 (0.5-2.5) 
1.0 (0.5-2.0) 
1.0 (0.5-2.0) 
 
2.5 (1.8-5.0) 
2.5 (1.0-4.3) 
2.0 (0.5-3.0) 
 
1.0 (0.5-2.0) 
1.0 (0-2.0) 
1.0 (0.5-2.0) 
 
0.007 
0.014 
0.116 
*p-value refers to univariate analysis between the IVT/ET and the standard ttm groups. 
**calculated of all patients alive with available data, i.e. at discharge n=142 (15 in IVT/ET group), 
at 6 months n=117 (12 in IVT/ET group), at 24 months n=86 (11 in IVT/ET group) 
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Table 2. Characteristics of the patients receiving i.v. thrombolysis or endovascular treatment 
Pat
ient 
Ag
e 
at 
str
ok
e 
(y) 
Dela
y to 
diag
nosi
s in 
hour
s 
Type 
of 
interv
entio
n 
Subst
ance 
used 
Stroke 
classif
ication 
Ves
sel 
invo
lved 
Base
line 
pedN
IHSS 
Complic
ations  
Recan
alisatio
n   
PSO
M 
disc
harg
e 
PS
OM 
6 
mo
nth
s 
PS
OM 
24 
mo
nth
s 
1  13.
8 
6 IVT tPA FCA ICA 
10 
none No 
2.0 1.5 1.0 
2  15.
6 
3 IVT tPA UE MC
A 
M1 13 
Asympto
matic 
ICH 
Partial 
5.0     
3 5.7 12 IVT tPA UE BA 25 none No 5.0 5.0 3.0 
4  5.7 14 IVT tPA FCA BA 24 none No 6.0  5.0  5.0 
5  5.8 48 IVT tPA CE BA 
25 
Subcuta
neous 
and 
mucosal 
bleeding 
No 
8.0 7.0 7.0 
6  11.
6 
3 IAT tPA UE MC
A 
M1 7 
none Compl
ete  
0.5 0.0 0.0 
7 14.
8 
3.5 Bridgi
ng 
and 
MT 
tPA UE MC
A 
M1 
22 
none Compl
ete 
0.5 0.5 0.5 
8  13.
6 
3 MT/IA
T  
 
Uroki
nase 
UE ICA 
15 
MMCAI 
hemicra
niectom
y 
Compl
ete  
2.0 1.0 0.5 
9  15.
2 
6 IAT tPA UE MC
A 
M1 
14 
MMCAI 
hemicra
niectom
y 
Partial  
4.0 6.0 6.0 
10  14.
1 
3 MT/IA
T  
tPA UE ICA 
17 
MMCAI 
hemicra
niectom
y 
Partial 
2.5 2.5 3.0 
11  2.1 2.5 MT/IA
T  
tPA CE MC
A 
M1 8 
none Compl
ete 
1.5 1 1.5 
12  8.9 4 IAT tPA UE MC
A 
M1, 
AC
A 13 
MMCAI 
hemicra
niectom
y 
NA 
5.0 3.5   
13  9.6 1 IAT tPA CE MC
A 
M1 12 
none NA 
0.0     
14  14.
8 
4 MT Eptifi
batid
e 
 
CE BA 
21 
MMCAI 
hemicra
niectom
y 
Partial  
 NA     
15  15.
3 
5 MT - UE ICA 
5 
none Partial 
 2.0     
16  9.7 10 IAT Uroki
nase 
FCA BA 12 None  Partial 
3.5 3.0 2.0 
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Table 3. Comparison of different recanalisation techniques 
 Thrombolysis 
(IVT/IAT)  
n=10 
Endovascular 
Thrombectomy (MT) 
n=6 
p-
value 
Age (years), median (range) 9.7 (5.7-15.6) 14.5 (2.1-15.3) 0.302 
pedNIHSS, median (range) 13 (7-25) 16 (5-22) 0.957 
Site of proximal vessel 
occlusion, n (%)  
ICA 
MCA 
ACA 
PCA 
BA 
SCA/PICA 
 
 
1 (10) 
5 (50) 
- 
- 
4 (40) 
- 
 
 
3 (50) 
2 (33.3) 
- 
- 
1 (16.7) 
- 
0.344 
Degree of recanalisation, n (%) 
Complete 
Partial 
No recanalisation 
 
1 (10) 
3 (30) 
4 (40) 
 
3 (50) 
3 (50) 
0 
0.078 
MMCAI, n (%) 2 (20) 3 (50) 0.486 
Stroke related mortality, n (%) 0 1 (16.7) 0.790 
PSOM, median (range) 
Discharge, n=15 
6 months, n=12 
24 months, n=11 
 
4.5 (0-8.0) 
3.5 (0-7.0) 
2.5 (0-7.0) 
 
1.8 (0.5-2.5) 
1.0 (0.5-2.5) 
1.0 (0.5-3.0) 
 
0.108 
0.074 
0.255 
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Table 4. Baseline characteristics of the cohort (pedNIHSS <10 in control group) 
 Whole cohort 
(66) 
Recanalization 
ttm (16) 
Standard ttm 
(50) 
p-value* 
Age (years), mean (SD) 8 (4.6) 11.0 (4.3) 7.0 (4.3) 0.002 
Sex, f (%) 28 (42.4) 5 (31.2) 23 (46) 0.389 
pedNIHSS, median (IQR) 12 (10-15.8) 13.5 (11.5-21.3) 12 (10-14.8) 0.26 
Fever, n (%) 4 (6.1) 0 (0) 4 (8.0) 0.565 
Seizure, n (%) 16 (24.2) 5 (31.2) 11 (22.0) 0.509 
Stroke classification, n (%) 
SVA 
FCA 
bilateral arteriopathy 
aortic/cervical 
arteriopathy  
cardioembolic 
undetermined 
multifactorial 
 
1 (1.5) 
10 (15.2) 
1 (1.5) 
11 (16.7) 
 
13 (19.7) 
27 (40.9) 
3 (4.5) 
 
0 
3 (18.8) 
0 
0 
 
4 (25.0) 
9 (56.2) 
0 
 
1 (2.0) 
7 (14.0) 
1 (2.0) 
11 (22.0) 
 
9 (18.0) 
18 (36.0) 
3 (6.0) 
0.287 
Site of stroke, n (%) 
Right 
Left 
Bilateral  
 
22 (33.3) 
29 (43.9) 
15 (22.7) 
 
6 (37.5) 
6 (37.5) 
4 (25.0) 
 
16 (32.0) 
23 (46.0) 
11 (22.0) 
0.812 
Site of proximal vessel 
occlusion  
ICA 
MCA 
ACA 
PCA 
BA 
SCA/PICA 
 
 
11 (16.7) 
39 (75.5) 
- 
3 (4.5) 
8 (12.1) 
5 (3.3) 
 
 
4 (25.0) 
7 (43.8) 
- 
- 
5 (31.2) 
- 
 
 
7 (14.0) 
32 (70.3) 
- 
3 (6.0) 
3 (6.0) 
5 (3.7) 
0.075 
Delay, n (%) 
<= 6h 
>6 - <=12h 
>12 - <=24h 
>24h 
 
29 (46.0) 
10 (15.9) 
10 (15.9) 
14 (22.2) 
 
12 (75.0) 
3 (18.8) 
0 (0) 
1 (6.2) 
 
17 (36.2) 
7 (14.9) 
10 (21.3) 
13 (27.7) 
<0.015 
Treatment, n (%) 
IVT 
IAT 
MT 
 
- 
- 
- 
 
5 (31.2) 
8 (50.0) 
3 (18.8) 
 
- 
NA 
Complications, n (%) 
symptomatic ICH 
asymptomatic ICH 
systemic bleeding 
any bleeding 
 
0 
2 (3.0) 
0 
1 (1.5) 
 
0 
1 (6.2) 
0 
1 (6.2) 
 
0 
1 (2.0) 
0 
0  
 
 
0.388 
 
0.075 
MMCAI, n (%) 16 (24.2) 5 (31.2) 11 (22.0) 0.452 
Stroke related mortality  4 (6.2) 1 (6.2) 3 (6.2) 1.0 
PSOM, median (IQR)** 
Discharge, n=65 
6 months, n=62 
24 months, n=61 
 
2.0 (1.0-4.0) 
1.5 (1.0-3.0) 
1.8 (0.5-3.0) 
 
2.5 (1.8-5.0) 
2.5 (1.0-4.3) 
2.0 (0.5-3.0) 
 
2.0 (1.0-4.0) 
1.5 (1.0-2.5) 
1.5 (0.5-2.8) 
 
0.323 
0.275 
0.619 
*p-value refers to univariate analysis between the IVT/ET and the standard ttm groups. 
**calculated of all patients alive with available data, i.e. at discharge n=65 (15 in IVT/ET group), 
at 6 months n=62 (12 in IVT/ET group), at 24 months n=61 (11 in IVT/ET group) 
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